Comgest Growth Europe S USD S AccRegister to Unlock Ratings |
Performance History | 31/03/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 17.7 | 24.4 | -16.8 | 16.6 | 10.4 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Islamic Equity - Other | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 19/04/2024 | USD 31.00 | |
Day Change | -0.16% | |
Morningstar Category™ | Islamic Equity - Other | |
ISIN | IE00B3ZL9H82 | |
Fund Size (Mil) 19/04/2024 | EUR 82.26 | |
Share Class Size (Mil) 19/04/2024 | USD 46.64 | |
Max Initial Charge | 4.00% | |
Ongoing Charge 21/03/2024 | 2.22% |
Investment Objective: Comgest Growth Europe S USD S Acc |
The investment objective of the Fund is to seek to create a professionally managed portfolio consisting of what, in the opinion of the Investment Manager, are high quality long-term growth companies having their headquarters or carrying out their predominant activities in Europe. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Franz Weis 10/03/2020 | ||
Pierre Lamelin 01/09/2013 | ||
Click here to see others | ||
Inception Date 08/12/2010 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
S&P Euro 350 Shariah TR EUR | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Comgest Growth Europe S USD S Acc | 31/12/2023 |
|
|
Top 5 Holdings | Sector | % |
ASML Holding NV | Technology | 8.37 |
Novo Nordisk A/S Class B | Healthcare | 7.77 |
Linde PLC | Basic Materials | 7.59 |
Essilorluxottica | Healthcare | 5.41 |
Nestle SA | Consumer Defensive | 5.34 |
Increase Decrease New since last portfolio | ||
Comgest Growth Europe S USD S Acc |